retatrutide mechanism triple agonist gip glp-1 glucagon Eli Lilly just announced striking Phase 3 results for retatrutide, an experimental “triple agonist” that acts on three gut-hormone targets at once. On the top dose, people lost an average of 28% Retatrutide dose schedule: complete week-by-week

At least 23 liters per day to support detoxification and absorption

Always consult your physician before starting any new supplement, especially if you have existing health conditions, take medications (including blood sugar medications, insulin, or metformin), or are pregnant or nursing

MORE: Thinking About Getting Liposuction

Adeem Azhar, MPharm, IPres Co-Founder and Chief Executive Officer Core Prescribing Solutions Qualified Clinical Pharmacist What does this mean for GP practices and PCNs

The global GLP-1 drugs market size began at US$ 52.95 billion in 2025 and is forecast to rise to US$ 58.05 billion by 2026